Biologics

Giving poorer countries access to medicines is a goal that should definitely be achieved as fast as possible. Would patents or giving access to patents accomplish …

Calypso Biotech BV (Amsterdam/Geneva), a spin-out of Merck-Serono, which became company in residence at JLABS in Beerse, Belgium, said it will use the proceeds to push …

The European Federation of Pharmaceutical Industries and Associations (EFPIA) criticised the manufacturing for export exemption for EU Regulation 469/2009 initially proposed by the EC and amended …

Under the licence and R&D agreement, Cytovant acquired the development and commercialisation rights for a research-stage T cell receptor (TCR) against the tumour antigen NY-ESO-1 as …

As Big Pharma’s development pipeline shows growing amounts of next-generation engineered antibody formats, further complexity has been added to the process development and biomanufacturing of biologics. …

Besides the expansion of its fermentation capacity to 5,000L, the CDMO added a state of the art process development laboratory to its new production site in …

Just Biotherapeutics started in 2015 with the mission to optimise and produce biologics at a price affordable even for low income countries. For the application of …

Pamplona-based CDMO 3P Biopharmaceuticals (3P) has announced Keensight Capital as its new major investor after previous major investor Infarco is refocussing on international expansion. By providing …

The growth in complex biologics is boosting the demand for innovative delivery mechanisms such as prefilled drug-delivery systems. Unfortunately, these systems often encounter issues with particulates …

Natalizumab, which is currently being marketed by Biogen, is a humanized monoclonal antibody against the cell adhesion molecule ?4-integrin. It is a disease-modifying therapy for RRMS. …